Mazou Ngou Temgoua on SCAF: Subclinical Atrial Fibrillation on Treatment with Apixaban or Aspirin
Mazou Ngou Temgoua, Contract hospital practitioner at Châteauroux-Le Blanc Hospital Center, shared on LinkedIn:
”Major Bleeding With Apixaban vs Aspirin
A Subanalysis of the ARTESiA Randomized Clinical Trial
Question In patients with subclinical atrial fibrillation (SCAF) treated with apixaban or aspirin, what are the sites, severity, and factors associated with major bleeding?
Findings In this subanalysis of the Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation (ARTESiA) randomized clinical trial including 3961 patients, although the rate of major gastrointestinal bleeding was higher with apixaban compared with aspirin, critical site, intracranial bleeding, and fatal bleeding were similar between arms.
Most major bleeding events in both groups were characterized by decreased hemoglobin and were not emergencies.
Meaning This study found that in patients with SCAF, apixaban increased major gastrointestinal bleeding compared with aspirin but intracranial and fatal bleeding events were similar between groups; most bleeding events were nonemergencies characterized by a decrease in hemoglobin.
Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial | Bleeding and Transfusion | JAMA Cardiology | JAMA Network”
Read the full article here.
Article: Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial
Authors: Deborah M. Siegal, Christian Sticherling, Jeff S. Healey, William F. McIntyre, Lene S. Christensen, Ratika Parkash, Thomas Vanassche, David Conen, Michael Gold, Christopher B. Granger, Jens Cosedis Nielsen, Marc Carrier, Daniel M. Wojdyla, Julia W. Erath, Lena Rivard, Valentina Kutyifa, David J. Wright, Renato D. Lopes
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 13, 2026, 04:49Martin Haluzík Shares A Study on GLP1-1RAs Use in Peripheral Artery Disease and DM
-
Jan 13, 2026, 04:37Shreya Agarwal and Bryce A Kerlin on The Impact of Advanced Hemostasis and Thrombosis Fellowship Trainings
-
Jan 13, 2026, 03:53Christian Schulze Shares New Data from DANGERSHOCK
-
Jan 13, 2026, 03:39Samwel Mikaye Breaks Down Peripheral Blood Smear
-
Jan 12, 2026, 15:07Aaron Iding and Colleagues on Additional Oxerutin Link to DVT
-
Jan 12, 2026, 14:46A Behcet Disease with Aortic Thrombosis: Alexandru Stieber Shares A Peculiar Case
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders